Examiner

Sheet 1 of 1 MAR 0 5 2001 Atty Docket No. Serial No. U.S. Dept of Commerce FORM PTO-1449 09/273,230 Patent and Trademark Office P0998D1 Applicant LIST OF DISCLOSURES CITED BY APPLICANT Claland et al. Filing Date Group (Use several sheets if necessary) 18 Mar 1999 1642 **U.S. PATENT DOCUMENTS** Examiner Class Subclass Filing Date Date Name Document Number initials 6,165,464 26,12,00 Hudziak et al. 248 OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) "Comparative efficacy of Herceptia in the nude mouse tumor xenografic model: IV bolus versus subcutaneous infusion. (Poster presented at the November 1999 AAPS National Meeting) (1999) 249 Kern et al. . Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. American Journal of Resolvatory Cell & Molecular Biology 9(4):448-454 (Oct 1993) 250 Ohnishi et al . Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal artibody" British Journal of Cancer 71(5):969-973 (May 1995) 261 Tokuda er al . In vitto and in vivo anti-tumous effects of a humanised monoclonal antibody against c-erbB-2 product Eritish Journal of Cancer 73(11):1362-1365 (Jun 1996) 252

DI whether or not citation is in conformance with MPEP 609, draw line through citation *Examiner Initial if reference considered if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered